The disialoganglioside GD2 is expressed on a wide spectrum of human tumor typesf including neuroblastomas and melanomas.
Introduction
Studies in both experimental animals and human patients have suggested that complement activation can play a role in tumor cytotoxicity in vivo (reviewed by Podack [1] ). In nude mice, injection of complement-reactive IgM and IgG2a, (but not complement-unreactive IgG1) monoclonal antibodies (MABs) against hepatitis B surface antigen suppresses the growth of xenografted human hepatomas (2) , whereas the administration of IgM, IgG2a, or IgG3 complement-fixing tumor-specific antibodies induces regression of established human melanoma and breast tumors (3) (4) (5) . In patients, injection of complement-fixing mouse MAbs directed against surface antigens of neuroblastomas and a variety of other tumor cell types have shown antitumor effects (6) (7) (8) . R24, an IgG3 antibody, when infused into patients with malignant mela-noma localizes at tumor site(s) and deposits C4 and C3 determinants (6) . Recently, the tumorcidal effects of specific antitumor antibody and complement have been exploited to destroy malignant cells in vitro. Purging of bone marrow with antibodies and complement in vitro has been shown to eradicate leukemia cells (9, 10) as well as a number of solid tumors (11) (12) (13) .
GD2 is a surface ganglioside expressed on a large number of malignancies including neuroblastomas, melanomas, sarcomas, and brain tumors. A series of MAbs specific for this oncofetal antigen has recently been described (14) (15) (16) . In the presence of these antibodies, human complement is consistently effective in killing neuroblastoma lines in vitro (1 1). The ability of the monoclonal antibodies to effect this cytotoxicity is dependent on the presence of surface GD2 antigen, since normal marrow cells as well as other tumor cell types that lack GD2 are not damaged. Among melanomas, however, several cell lines have been identified which, despite binding of complement-fixing antibodies, are resistant to in vitro complement killing (17, 18) . This finding has indicated that factors other than surface expression oftarget antigen must play a role in the susceptibility of these cells to complemnent-mediated cytotoxicity.
Decay-accelerating factor (DAF)' is a cell membrane-associated inhibitor of complement activation (19, 20) which provides protection for blood cells from potential injury arising from attack by autologous complement proteins. By interfering with the assembly of autologous C3 (C4b2a and C3bBb), and C5 convertases (C4b2a3b and C3bBb3b) (20) (21) (22) , DAF blocks the amplification steps of both the classical and alternative complement pathways on host cell surfaces. DAF is present in the membranes of erythrocytes, platelets, neutrophils, monocytes, and lymphocytes (23, 24) Antibody-dependent cell-mediated tumor cytotoxicity (ADCC).
Target cells were prepared as described above. Peripheral blood mononuclear cells obtained by Ficoll-Paque gradient were used as effector cells at various effector/target ratios in a standard 4-h '1Cr-release assay. Percent specific release was calculated using the same formula as was used for complement cytotoxicity. Total release was obtained by lysis with 10% SDS, and background lysis was assessed in the absence of effector cells.
Radiolabeling and quantitation ofC3 uptake. C3 was labeled with 125I using Iodogen (Pierce Chemical Co., Rockford, IL) according to the manufacturer's instructions. Unreacted iodide was removed by gel filtration through G-25 (Pharmacia Fine Chemicals).
To determine the amount of C3b uptake, 200 Ml of 10 tumor cells/ml were mixed with 50 Ml of 500 Mg/ml of 3F8 and 200 ul of 1:8 dilution of human serum containing 106 cpm of radiolabeled C3. The reaction mixture was incubated at 37°C and stopped by centrifugation and cooling to 4°C at various times between 0 and 90 min. Cell pellets were counted in a gamma counter. Calculations of the amount of C3 bound per cell were based on a normal C3 concentration in undiluted human serum of 1.4 mg/ml. A molecular mass of 175,000 daltons was used for the calculation of the number of C3b molecules per cell.
Reactive lysis. 5"Cr-labeled tumor cells in serial dilutions (1:4 to 1:256) ofhuman serum were incubated at 37°C for I h with preformed cobra venom factor Bb complexes as previously described (29) . After dilution with ice-cold buffer and centrifugation, percent 5"Cr release was measured.
Results
Quantitation of DAF levels in tumor cell lines. Total DAF contents of various tumor cell lines as measured by two-site IRMA employing anti-DAF monoclonals are shown in Table  I . Levels of DAF in normal blood elements established in previous studies (23) Comparative complement sensitivity of DAF-positive and -negative melanoma lines. To study the functional significance of DAF expression by tumor cells, two GD2-positive melanoma lines (HT-144 and SKMel-l), which differed with respect to the absence or presence of DAF, were selected for analysis. FACS analyses (Fig. 1) showed that the HT-144 and SKMel-1 lines were both strongly positive for GD2 and, with respect to this antigen, exhibited cell populations with comparable mean fluorescence. In contrast, when examined for surface DAF, SKMel-1 cells were nearly or totally DAF negative, whereas HT144 cells were uniformly positive (Fig. 1) .
The sensitivities of the two cell lines to complement-mediated cytotoxicity were next compared in 5'Cr-release assays. Irrespective ofthe dilution ofcomplement (serum) used (Fig. 2  A) and the concentration of the GD2-sensitizing antibody employed (data not shown), HT144 cells exhibited nearly complete resistance to complement killing. In contrast, under identical conditions, SKMel-l cells were readily killed, even at a 1:32 dilution of complement (serum).
To determine if the greater lytic susceptibility of the SKMel-1 line is a nonspecific characteristic of this tumor rather than a reflection of a specific difference in response to complement, the two cell lines were compared in their susceptibility in ADCC. In contrast to the results obtained in the complement assays, in ADCC the HT-144 and SKMel-l cell lines exhibited equivalent cytotoxicity. The comparable extent of 5"Cr release in ADCC indicated that the sensitivity of SKMel-1 cells to complement did not derive from an increased fragility of the membranes of these cells and likewise that the lack of lysis of HT-144 in complement assays was not a result of the inability of this cell type to release chromium when killed (Fig. 2 B) .
Role ofDAF activity in resistance ofHT-144 cells to complement-mediated lysis. In order to establish whether the complement resistance of HT 144 cells compared to that of SKMel-1 cells is a consequence of DAF action, the effect on with increasing concentrations of pooled anti-DAF MAbs. An aliquot of the anti-DAF-treated cells was then tested for lysis by the addition of 3F8 followed by human complement. As a control, another aliquot of the anti-DAF-pretreated cells was incubated with complement in the absence of 3F8. As additional controls, in place of anti-DAF monoclonals, 5"Cr-labeled HT-144 target cells were preincubated with either (a) anti-Ia (L243), (b) anti-HLA-ABC (W6/32), (c) anti-HLA monomorphic (BB7.5) MAbs, or (d) medium alone and then tested as above with 3F8 followed by complement. As summarized in Fig. 3 Fig. 4 . At all complement concentrations, augmentation by anti-DAF antibodies of complement sensitivity ofthe HT-144 cells was dose dependent. Despite the inability ofpooled anti-DAF MAbs alone (Fig.  2 A) or of the above control MAbs in conjunction with 3F8 ( Fig. 3) to induce complement cytotoxicity, additional experiments were performed to rule out the elicitation of a cooperative effect between the anti-DAF monoclonals and 3F8 in activating complement. For this purpose, the pooled anti-DAF MAbs were digested with pepsin and anti-DAF F(ab')2 fragments isolated. Analysis of the products of the digestions on SDS-PAGE showed bands at 29 and 27 kD consistent with the presence of F(ab')2 fragments exclusively. No bands corresponding to uncleaved H-chains (51 kD) were observed in the gels and no intact IgG molecules were detectable by chromatography on Superose-12. Substitution of the pooled anti-DAF F(ab')2 for intact antibodies in the complement cytotoxicity assays using hancement of killing (Fig. 5) . Quantitative dose response experiments (Fig. 6) showed that the pooled F(ab')2 and pooled anti-DAF IgG functioned with virtually equivalent efficiency.
When the deposition of C3 on these cells was studied, a peak level of 298,000 molecules of C3b per cell was observed (1:16 serum, 15 min at 37°C) for SKMel-l in the presence of 3F8. In contrast, only 69,000 molecules were deposited on HT-144. However, when DAF function in HT-144 cells was blocked by preincubation with anti-DAF antibodies, peak uptake of C3b on these cells rose to 269,000 molecules per cell.
In order to determine if the difference in complement sensitivities of the two melanoma lines could derive from differences in the function of homologous restriction factor, in addition to differences in DAF, the SKMel-l and HT-144 cell lines were tested in reactive lysis using cobra venom factortreated serum. In contrast to type III PNH human erythrocytes, which showed 30% lysis in 1:256 dilution of serum and > 80% lysis in 1:64 serum, both tumor types gave < 5% lysis in 1:4 serum (data not shown). When DAF function of HT-144 was blocked by preincubation with anti-DAF antibodies, no increase in the lysis of the cells in cobra venom factor-treated serum was observed. action. In addition, studies with cobra venom factor serum showed that the differences in complement sensitivities of the two melanoma cell lines were not attributable to different sensitivities to C5b-9 and thus to differences in expression of homologous restriction factor, another protein restricting the sensitivity of host cells to autologous complement attack (31) .
The mechanisms by which cells regulate DAF expression are not yet fully understood. It is possible that in certain cell types, DAF is not expressed or that DAF expression is a late differentiation event. Such a mechanism, in principle, could account for the finding that neuroblastoma lines are uniformly DAF negative, but might not as readily explain all the variability of DAF expression within different lines of other tumor types, i.e., melanoma and breast carcinomas. In cells that normally express DAF, neoplastic transformation could result in a failure to express DAF. This could arise from downregulation of DAF gene transcription. Alternatively, alterations in the cellular machinery involved in DAF anchorage in membranes could lead to lack of DAF expression. Previous studies (32, 33) have shown that DAF is anchored in cell membranes via a carboxy-terminal glycolipid containing inositol phospholipids. This anchoring structure is added to the carboxyterminus of DAF polypeptide during a posttranslational modification that occurs prior to the processing of pro-DAF in the Golgi apparatus (32) . Perturbations in the synthesis ofthis glycolipid unit or in its incorporation into DAF could preclude DAF surface expression. In view of the susceptibility of the glycolipid-anchored protein in some cell types to PI-PLC cleavage (32, 33) , activation of endogenous PI-PLC enzymatic activity could lead to loss of DAF in some tumor cell lines. However, analyses of culture supernatants of DAF-negative SKMel-1 by IRMA did not reveal immunoreactive DAF molecules. Moreover, hybridization analyses employing DAF cDNA (34) showed that DAF mRNA transcripts were present in HT-144 cells but not in SKMel-1 cells consistent with an effect at the transcription level. Further experiments will provide insights into mechanism(s) operative in DAF nonexpression by other tumors. Whatever these mechanisms, the downregulation of DAF expression could play a facilitory role in tumor surveillance in vivo for some tumors.
In addition to direct tumorcidal actions, complement activation can impact indirectly on tumor growth through effects on vessel permeability, cell trafficking, and possibly sensitization oftumors to cellular effectors. Local formation ofC3a can increase both blood flow and diffusion of proteins into tumor containing tissues. The generation of C5a may also increase the influx of phagocytes to tumor sites. The deposition of iC3b (or C3b) on target cell surfaces has been demonstrated to promote ADCC activity of lymphocytes (35) . The increase in recruitment of effector cells to tumor sites and the enhancement in the efficiency of cell-dependent modalities of tumor killing should contribute to cytotoxicity. In principle, even a partial block in DAF inhibitory function, might result in sufficient activation of the cascade to retard tumor propagation.
The abrogation of DAF function in tumor cells may have clinical implications for targeted immunotherapy using antitumor antibodies. As done in this study, it may be possible to employ tumor specific antibodies in conjunction with anti-DAF F(ab')2 fragments to enhance efficiency of tumor killing. However, the clinical usefulness of this approach could be complicated by the limitations that normal tissues could com- 
